Adolescent Obesity, Child Development, Health Behavior
Conditions
Keywords
adolescent, probiotics, COVID-19, overweight, obese
Brief summary
Probiotic intervention has been currently suggested to provide supportive benefits in promoting health, including alleviating disease symptoms, protecting against diarrhea and respiratory infection, affecting growth and modulating the immune system by improving the beneficial gut microbiota colonization, giving direction on the gut-lung-axis pathway. This indicates that probiotics may become alternative to improve nutrition and reduce the risk of viral infections which may reduce the risk against Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Introduction to probiotics during adolescence can alleviate inflammation and invert dysbiosis. However, evidence on the effect of probiotic supplementation on enhancing antibody response to SARS COV-2 in adolescents is lacking. Moreover, previous studies showed the potential effect of probiotic supplementation to improve overweight and obesity in adolescents. A bi-directional relationship exists among nutrition, infection, and immunity as changes in one element will affect the others. The main objective of this study is to investigate the effect of dietary modulation of overweight and obese adolescent's gut microbiota through probiotic supplementation combined with healthy eating and physical activity counseling and psychosocial stimulation on nutritional status and antibody response to COVID-19 vaccination. This trial will conduct a 20-week intervention for overweight and obese adolescents.
Detailed description
The adolescence period is the transition from childhood to adulthood. Adolescents are vulnerable to many biomedical exposures, such as a low-quality diet, fewer fruits and vegetable intake, low physical activities, smoking habits, and alcohol consumption; and non-biomedical aspects such as mental depression, parental distress, and household income, which were known to be associated with increased risk of many health outcomes. Obese adolescents are vulnerable to many infections, poor disease outcomes and complications, and lower antibody response to vaccinations. Studies that have investigated Covid-19 incidence in overweight and obese individuals are still scarce. Adolescence is also a sensitive period to microbial change or dysbiosis due to practicing poor diet, low physical activity, inadequate sleep, stress, and substance use (smoking, drugs, and alcohol). Despite the existing prevalence of SARS-COV-2 infections is increasing in adolescents, and the vaccine program is not prioritized in this population, making the prevention strategy for SARS-COV-2 infection may become less effective in this population. Besides, low-quality diet and lifestyle habits and family cluster transmission at home are often not fully addressed in the policy. These factors may be the contributors to the potential highest COVID-19 exposure for children and adolescents. Since exposure among adolescents is linked to serious adverse health effects, effective interventions to improve nutritional outcomes and reduce the risk of COVID-19 infection will provide substantial long-term returns. However, such interventions for adolescents in Indonesia and globally are lacking. This study is a randomized clinical trial (RCT) and placebo parallel controlled study. The research will be conducted in junior and senior high schools in Jakarta, Surabaya, and Yogyakarta, Indonesia. In light of COVID-19 outbreak, if face-to-face activities are permitted by (1) national government (Indonesian Ministry of Health), (2) local government (DKI Jakarta), (3) the university, (4) Data Safety Monitoring Board, and (5) by consent of the subject, then the activities need to be strictly adjusted with the COVID-19 prevention measures for both personnel and subjects. All personnel and subjects who will be involved in the activities are required to fill out the COVID-19 symptom screening form prior to the visit and have been vaccinated with a complete dose.
Interventions
DIETARY_SUPPLEMENTProbiotics
Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
BEHAVIORALCounselling on healthy eating, physical activity, and psychosocial stimulation
Counselling on healthy eating, physical activity, and psychosocial stimulation.
DIETARY_SUPPLEMENTPlacebo probiotics
Maltodextrin
Sponsors
Gadjah Mada University
Universitas Airlangga
University of Melbourne
The Indonesia Endowment Funds for Education, Ministry of Finance Indonesia
Indonesia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Quadruple (Participant, Enumerator, Investigator, Outcomes Assessor) Participant, enumerator, investigator, and outcomes assessor do not know which one is the intervention product or placebo.
Intervention model description
The product will be given to 440 overweight/obese adolescents, 220 adolescents as an intervention group, and 220 overweight/obese adolescents as a control group
Eligibility
Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
1. living in Jakarta, Surabaya, and Yogyakarta City for at least 6 months permanently; 2. apparently healthy; 3. male and female, age 12-17 years old; 4. overweight or obese (BMI-for-age z-score \>+1SD); 5. have completed at least two dosages of COVID-19 vaccine, the vaccine must be CoronaVac® (Sinovac); 6. minimal 6 months post vaccinated prior to recruitments. 7. parents willing to sign the informed consent and adolescents give informed assent; 8. Must have an active health insurance, for instance BPJS or similar health insurance.
Exclusion criteria
1. having a history of COVID-19 infection within the last month confirmed by PCR or antigen from health care facilities or independent laboratory; 2. having a history of chronic and non-communicable diseases, congenital diseases, and disabilities; 3. reported current diagnosed as suspected active Tuberculosis (primary lung TB, miliary TB, bleeding cough bone TB, meningitis TB); 4. having a history of gastrointestinal or malabsorption disorder (such as celiac disease and inflammatory bowel disease) within the last three months or during the study; 5. taking antibiotics during 2 weeks before the start of the study (adolescents will be included after 3 weeks of last antibiotic intake); 6. taking other medications or having diseases that may influence the immune response - i.e. immune deficiencies, immunosuppressants medications, blood transfusion or other blood products; 7. taking insulin and/or anti-dyslipidemia medication; 8. being pregnant and/or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BMI-for-age z-scores (BAZ) | 5, 10, 15, and 20 weeks | Change in BAZ obtain from anthropometric measurements, i.e., weight (kg) and height (m) converted to BMI |
| Immunoglobulin G (IgG) specific to SARS-COV-2 titer concentrations | 10 and 20 weeks | Change in IgG specific to SARS-COV-2 titer concentrations assessed by electro chemiluminescence immunoassay (ECLIA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Monoclonal antibody affinity against SARS-COV-2 | 10 and 20 weeks | Change in equilibrium dissociation constant (KD) of monoclonal antibody against SARS-COV-2 spike protein measured by competitive ELISA |
| α-gut microbiota diversity | 20 weeks | Change in α-diversity measured by 1) Chao1, 2) phylogenetic diversity, and 3) the Shannon index. |
| Dietary quality | 5, 10, 15, and 20 weeks | Change in score of dietary quality assessed by Healthy Eating Index 2015 from 24 hour recalls data |
| Secretory Immunoglobulin A (sIgA) specific to SARS-COV-2 titer concentrations | 10 and 20 weeks | Change in sIgA specific to SARS-COV-2 titer concentrations assessed by competitive ELISA |
| β-gut microbiota diversity | 20 weeks | Change in β -diversity: as the variability in community composition (the identity of taxa observed) among samples |
Other
| Measure | Time frame | Description |
|---|---|---|
| Gut integrity (zonulin) | 20 weeks | Changes in the level of serum zonulin assessed by ELISA and Changes in the level of fecal zonulin assessed by ELISA |
| Gut integrity (occludin) | 20 weeks | Changes in the level of fecal occludin assessed by ELISA |
| Gut inflammation | 20 weeks | Changes in concentration of fecal calprotectin assessed by ELISA |
| Gut microbiota profiling | 20 weeks | Changes in composition of gut microbiota assessed by next-generation sequencing (NGS) |
| Short Chain Fatty Acids (SCFA) | 20 weeks | Change in concentration of the SCFA by gas chromatograph |
| Physical activity | 5, 10, 15, and 20 weeks | Changes in International Physical Activity Questionnaire for Adolescent (IPAQ-A) score, the minimum is 0 metabolic equivalents of task (MET) minutes/week, and the maximum score is 3000 MET minutes/week. Higher score means better outcome. |
| Body image | 20 weeks | Changes in Body Shape Questionnaire-34 (BSQ-34) score. The minimum score is 34, and the maximum is 204. Higher score means worse outcome |
| SARS-COV-2 infection | 20 weeks | Changes in proportion of symptomatic COVID-19 and positive PCR |
| Self-esteem | 20 weeks | Changes in Rosenberg Self Esteem Scale. The minimum score is 0, and the maximum score is 37. Higher scores mean better outcome. |
| Quality of life score | 20 weeks | Changes in the score of Youth Quality of Life for adolescents-Research version (YQOL-R). The minimum score is 0, and the maximum score is 100. Higher scores mean better outcome. |
| Morbidity | 5, 10, 15, and 20 weeks | Type and frequency of illness |
| Mortality | 5, 10, 15, and 20 weeks | Type and frequency of illness |
| Wechsler Intelligence Scale for Children score | 20 weeks | Changes in Wechsler Intelligence Scale for Children (WISC). The minimum score is 70, and the maximum score is 159. Higher scores mean better outcome. |
| Brain Derived Neurotropic Factor level | 20 weeks | Changes in level of Brain Derived Neurotropic Factor (BDNF) assessed by ELISA |
| Anemia status | 20 weeks | Changes in hemoglobin concentration |
| Depression | 20 weeks | Changes in Patient Health Questionnaire for Adolescents (PHQ-A) score. The minimum score is 0, and the maximum is 27. Higher scores mean worse outcome. |
| Body height | 5, 10, 15, and 20 weeks | Changes in height-for-age z-score by anthropometric measurement |
| Abdominal obesity (waist circumference) | 5, 10, 15, and 20 weeks | Changes in waist circumference by anthropometric measurement |
| Abdominal obesity (waist-hip ratio) | 5, 10, 15, and 20 weeks | Changes in waist-hip ratio by anthropometric measurement |
| Middle upper arm circumference | 5, 10, 15, and 20 weeks | Changes in middle upper arm circumference by anthropometric measurement |
| Immunoglobulin M (IgM) against SARS-Cov-2 | 10 and 20 weeks | Changes in IgM titer concentrations assessed by electro chemiluminescence immunoassay (ECLIA) |
| Neutralizing antibody against SARS-Cov-2 | 10 and 20 weeks | Changes in total neutralizing antibody titer assessed by Surrogate Virus Neutralization Test (sVNT) |
Countries
Indonesia
Contacts
Primary ContactRina Agustina, PhD
Backup ContactRahyussalim Rahyussalim, PhD
Outcome results
None listed